Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1/2 4Phase 3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 3Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 4NIH 2INDUSTRY 1

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 4Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 3Thymoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1

Interventions

Specimen Handling 176Magnetic Resonance Spectroscopy 138Biopsy 102pembrolizumab 81Carboplatin 79Cisplatin 71Nivolumab 65Cyclophosphamide 64Paclitaxel 54Radiotherapy 48Gemcitabine 43durvalumab 39Doxorubicin 35Bevacizumab 34Fluorouracil 33venetoclax 32Dexamethasone 31Rituximab 30atezolizumab 29Radiation 29Capecitabine 28Lenalidomide 27Etoposide 27Prednisone 26Oxaliplatin 26Injections 26Pemetrexed 25Docetaxel 25olaparib 23fludarabine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × avelumab × 30 days × Clear all
NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

BicycleTx Limited

Phase 2 Active not recruiting
375 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03076554 2026-05-22

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT03324282 2026-05-22

GCISAVE

University Hospital, Bordeaux

Phase 2 Terminated
65 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT03494322 2026-05-20

EACH

University College, London

Phase 2 Completed
16 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT05947500 2026-05-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT06892860 2026-05-06

DISCUS

Queen Mary University of London

Phase 2 Recruiting
320 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05327686 2026-05-04

SAMURAI

NRG Oncology

Phase 2 Recruiting
240 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡